SAFETY AND EFFICACY STUDY OF THE COMBINATION DACLATASVIR (60 MG), SOFOSBUVIR (400 MG) AND RIBAVIRIN (WEIGHT-BASED DOSING) FOR 12 OR 16 WEEKS IN SUBJECTS WITH GENOTYPE 3 CHRONIC HCV INFECTION WITH OR WITHOUT PRIOR TREATMENT EXPERIENCE AND ADVANCED FIBROSIS OR COMPENSATED CIRRHOSIS: